Last updated:

Tirzepatide 10mg
Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in incretin biology and metabolic signalling research.
What is Tirzepatide?
Tirzepatide is a peptide agonist with activity at both the GIP receptor and GLP-1 receptor. This dual-receptor profile is a major focus of incretin research and distinguishes Tirzepatide from compounds that primarily target GLP-1 alone.
Research examines how coordinated GIPR and GLP-1R signalling influences endocrine responses and metabolic pathways. As with all receptor research, observed effects depend on the experimental system and should be interpreted within the specific evidence available.
Metabolic research
Tirzepatide 10mg · SKU TR10
Dual incretin-receptor signalling
In stock · $70.00 AUD
Dual incretin-receptor signalling.
GIP and GLP-1 are incretin hormones that signal through distinct receptors. Tirzepatide provides a model for investigating simultaneous agonism of both receptor systems.
Researchers may compare receptor potency, downstream signalling and metabolic markers with those of single-receptor or triple-receptor compounds.
Common research themes.
Investigation of glucose-dependent insulinotropic polypeptide receptor signalling.
Research into glucagon-like peptide-1 receptor pathways.
Study of coordinated signalling across two incretin receptors.
Comparison with GLP-1-only agents and triple agonists such as Retatrutide.
How Retatrutide, Tirzepatide, Semaglutide and Liraglutide differ.
These molecules are often grouped together because they all involve GLP-1 receptor signalling, but their receptor profiles are not the same. The main pharmacological distinction is whether the molecule targets GLP-1 alone or combines GLP-1 activity with additional metabolic receptor pathways.
The comparison below describes receptor targets and development status rather than ranking efficacy, safety or suitability. Approved branded medicines and ARVEONIX research catalogue products should not be treated as interchangeable formulations.
| Molecule | Receptor targets | Agonist profile | Current research / regulatory context |
|---|---|---|---|
| Liraglutide | GLP-1 receptor | Single GLP-1 receptor agonist | Established GLP-1 medicine with approved therapeutic formulations. |
| Semaglutide | GLP-1 receptor | Single GLP-1 receptor agonist | Established GLP-1 medicine with approved therapeutic formulations. |
| Tirzepatide | GIP + GLP-1 receptors | Dual incretin receptor agonist | Approved dual GIP/GLP-1 therapeutic molecule in regulated formulations. |
| Retatrutide | GIP + GLP-1 + glucagon receptors | Triple receptor agonist | Investigational molecule in Phase 3 development; not yet approved for public therapeutic use. |
In simplified terms, the progression is from single-receptor GLP-1 agonism with liraglutide and semaglutide, to dual GIP/GLP-1 agonism with Tirzepatide, and then to triple GIP/GLP-1/glucagon agonism with Retatrutide. More receptor targets do not, by themselves, establish that one compound is superior to another.
Research considerations.
Research findings should always be interpreted within the experimental system in which they were produced. Cell, receptor, tissue, animal and human studies can answer different questions, and results from one model should not automatically be treated as established outcomes in another.
ARVEONIX product pages therefore focus on molecule identity, pathway biology and published research themes rather than presenting experimental observations as guaranteed effects. The information here is not a dosing, treatment or individual-use recommendation.
Use the ARVEONIX calculator for concentration, liquid-volume and U-100 arithmetic using values you enter.
Tirzepatide FAQs.
What is Tirzepatide?
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors.
Which receptors does Tirzepatide target?
It targets GIPR and GLP-1R.
How is Tirzepatide different from Retatrutide?
Retatrutide additionally targets the glucagon receptor, giving it a triple-agonist research profile.
What is incretin signalling?
It refers to signalling involving gut-derived hormones such as GIP and GLP-1 and their receptors.
What strength is ARVEONIX Tirzepatide?
This catalogue product is Tirzepatide 10mg under SKU TR10.
What areas are studied?
Incretin biology, receptor pharmacology and metabolic signalling.
Does this page provide dosing instructions?
No.
Related products.
Other ARVEONIX catalogue items you may want to view.
Need concentration or U-100 unit conversions?
Use the ARVEONIX peptide reconstitution calculator to convert vial amount, diluent volume, target dose and syringe units for research planning.